Navigation Links
New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture
Date:10/10/2008

Leading researchers in academia and industry reveal powerful effects of recombinant lactoferrin (tradename: Lacromin) in mammalian cell culture

leading to a significant boost in productivity.

FORT COLLINS, Colo., Oct. 10 /PRNewswire/ -- A recently published study in the scientific journal In Vitro Cellular & Developmental Biology revealed that recombinant lactoferrin (tradename: Lacromin, see http://www.Lacromin.com) is a strong growth factor for promoting cell growth and cell productivity across a variety of cell lines, including intestinal cells, hybridoma cells, osteoblast cells and embryonic kidney (293) cells.

A global collaborative research effort led to the findings. The study included research conducted by two prestigious international research institutions: University of Auckland in New Zealand and Barts & The London Queen Mary's School of Medicine & Dentistry in London. Also, cell culture industry researchers at the following companies contributed to these findings:

-- HyClone Inc in Logan, Utah;

-- KC Bio in Kansas City, Missouri; and

-- InVitria in Fort Collins, Colorado.

Dr. Ning Huang, Vice President of Research and Development for InVitria, coordinated the study entitled, "Bioactive recombinant human lactoferrin, derived from rice, stimulates mammalian cell growth (1)."

"In working with research collaborators in the industry and leading academic centers around the world, recombinant lactoferrin has been shown to promote cell growth and productivity in a variety of cell lines and also improves antibody product yields in mammalian cell culture," said Dr. Huang. "Since recombinant lactoferrin is well defined, it is an important component for adapting cells and transitioning cells from serum to animal free and completely defined cell culture media."

"We have discovered that recombinant lactoferrin is an important growth factor in bone cell culture media," said Professor Jillian Cornish, Department of Medicine, Faculty of Health and Medical Sciences at University of Auckland. "Not only did we see improved growth of osteoblasts, but we also found that growth increased with greater amounts of recombinant lactoferrin."

About InVitria (http://www.InVitria.com)

InVitria has developed cell culture media components that enhance productivity, safety and time to market for companies in the biopharmaceutical, mammalian cell culture, regenerative medicine, cell therapy, stem cell and diagnostics industry. InVitria's recombinant human lactoferrin called Lacromin (http://www.Lacromin.com) was utilized in this study.

For more detailed product information requests or to order re-prints of the above-mentioned article contact InVitria by e-mail or phone.

E-mail: info@InVitria.com Phone: 1-800-916-8311

(1) Huang, N. et al. Bioactive recombinant human lactoferrin, derived from

rice, stimulates mammalian cell growth. In Vitro Cellular &

Developmental Biology. September 19, 2008 (E-publication Date).


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Facet Solutions Completes Facet Joint and Disc Replacement Study
2. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
3. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
4. Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
5. Eklin Medical Surpasses 1,000th RapidStudy(R) Digital Radiography System Installation Featuring Canon DR Technology
6. Oil palm plantations are no substitute for tropical rainforests, a new study shows
7. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
8. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
9. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
10. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... February 9, 2016 Three-Year Initiative Supports ... to Take Part in Life-Changing Camp ... designed to positively affect the lives of children born with rare ... --> SHPG ) is announcing a new initiative designed to ... well as the future of rare disease care. --> ...
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)... ... 08, 2016 , ... Thomas J. Todorow has joined the ... for Corporate Services and the Chief Financial Officer at The Children’s Hospital of ... Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. , an ... technology, today announced the availability of AllegroGraph 6, the leading Semantic Graph Database ... Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph Database to ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ... "Emotion Detection and Recognition Market by Technology ... Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020" report to ... ) has announced the addition of the ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):